|
|
|
Volumn 19, Issue 8, 2006, Pages 58-68
|
|
Biopharmaceuticals: Approval trends in 2005
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BEVACIZUMAB;
CALCIUM PHOSPHATE;
FORTICAL;
GALSULFASE;
GROWTH FACTOR;
HUMAN GROWTH HORMONE;
HYALURONIDASE;
HYLENEX;
INSULIN DETEMIR;
MECASERMIN RINFABATE;
MONOCLONAL ANTIBODY;
N ACETYLGALACTOSAMINE 4 SULFATASE;
NATALIZUMAB;
NUCLEIC ACID;
OMALIZUMAB;
PALIFERMIN;
PLATELET DERIVED GROWTH FACTOR BB;
RECOMBINANT ERYTHROPOIETIN;
RECOMBINANT HUMAN HYALURONIDASE;
RECOMBINANT HUMAN N ACETYLGALACTOSAMINE 4 SULFATASE;
RECOMBINANT HUMAN PLATELET DERIVED GROWTH FACTOR BB;
RECOMBINANT PROTEIN;
RECOMBINANT SOMATOMEDIN C;
SALCATONIN;
UNCLASSIFIED DRUG;
ANAPHYLAXIS;
ANTIBODY PRODUCTION;
ASTHMA;
CLINICAL TRIAL;
COLON CARCINOMA;
DIABETES MELLITUS;
DRUG APPROVAL;
DRUG INDICATION;
DRUG MARKETING;
FEVER;
GROWTH DISORDER;
HEADACHE;
HUMAN;
HYPERTROPHY;
HYPOGLYCEMIA;
INFUSION REACTION;
INJECTION SITE REACTION;
LYMPHOID TISSUE;
LYMPHOID TISSUE HYPERTROPHY;
MALIGNANT NEOPLASTIC DISEASE;
MARKET;
MAROTEAUX LAMY SYNDROME;
MONEY;
MUCOSA INFLAMMATION;
PERIODONTAL DISEASE;
POSTMENOPAUSE OSTEOPOROSIS;
PROCEDURAL SITE REACTION;
RECTUM CARCINOMA;
REVIEW;
UPPER RESPIRATORY TRACT INFECTION;
VIRUS INFECTION;
|
|
EID: 33747164744
PISSN: 1542166X
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (7)
|
|
References (6)
|
